Advances of the contemporary treatment of hypertension and hypercholesterolemia by a new fixed combination
Authors:
Hana Rosolová
Authors‘ workplace:
Centrum preventivní kardiologie UK LF v Plzni, 2. interní klinika FN Plzeň
Published in:
Vnitř Lék 2022; 68(1): 64-67
Category:
Overview
Parallel occurrence of high blood pressure and high plasma cholesterol level is very frequent, in our population in 30 %, and brings multiplicative higher risk for atherosclerotic cardiovascular diseases. On the other hand the contemporary treatment of them reduces that risk synergically. New fixed combination pill of rosuvastatin and ramipril (Kastel) is very felicitous choice for patients with hypercholesterolemia and mild hypertension, in which two antihypertensive drugs are not required immediatelly.
Keywords:
hypertension and hypercholesterolemia treatment – cardiovascular diasease prevention – the fixed combination of ramipril and rosuvastatin
Sources
1. Strehlow K, Wassmann S, Bohm M et al. Angiotensin AT1 receptor over‑expression in hypercholesterolemia. Ann Med 2000;32:386-389.
2. Stulak JM, Lerman A, Caccitolo JA et al. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis 2001;154:195-201.
3. Wohlfahrt P, Krajčoviechová A, Bruthans J et al. Hypertenze a hypercholesterolemie v české populaci. Vnitř. Lék. 2016:62:863-867.
4. Thomas F, Bean K, Guize I et al. Combined effect of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (< 55 years) men and women. Eur Heart J 2002;23:528-535.
5. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease overal findings and differences by age for 316 099 white men. MRFIT Research group. Arch Intern Med 1992;152:56-64.
6. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Europ Heart J, 2018;39:3021-3104.
7. Borghi C, Cicero f, Bacchelli S et al. Survival of Myocardial Infarction Long‑term Evauation (SMILE) study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril a post hoc analysis of te SMILE tril. Fundam Clin Pharmacol 2009;23:641-648.
8. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).Eur Heart J 2019; doi:10.1093/eurheartj/ehz455
9. Briasoulis A, Agarwal B, Valachis A et al. Antihypertenive effects of statins: a metaanalysis of prospective controlled studies. J Clin Hypertens 2013;15:310-320.
10. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25:484-491.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 1
Most read in this issue
- A cirrhotic patient in an internal medicine ward
- Cholesterol measurement and current guidelines
- Levotyroxin
- How to run an internal medicine department: head physician – trainer